Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing—A Prospective Feasibility StudyB.M. Berger, Ariane Aigelsreiter, Emina Talakić et al.|Cancers|2021Cited by 4
Testing and clinical implications for non‐V600 <i>BRAF</i> mutations in metastatic <i>NRAS</i> <sup> <i>mt</i> </sup> melanomaGeorg Richtig, Ariane Aigelsreiter, Erika Richtig et al.|British Journal of Dermatology|2016Cited by 3